Alcon Laboratories, Inc.

Alcon Research, Ltd.

Alcon, Inc.

Other

Alcon Manufacturing, Ltd.

Astellas Pharma Gmbh

Ultrasci Discovery Llp

Hwang-Hsing Chen

Jesse Albert May

Thomas R Dean

Najam A Sharif

Mark R Hellberg

Bryon Severns

Abdelmoula Namil

Andrew Rusinko

Masood A Chowhan

Iok-Hou Pang

Ernesto J Castillo

Alan John Henderson

Mark Hadden

Keith D Combrink

Cheng Guo

Glenn D Stafford, Jr

Brian DuPr E

Anura Dantanarayana

Suchismita Mohapatra

Ganesh Prasanna

Biocidal branched polymeric biguanide compounds are made by polycondensation of sodium dicyanamide and a Afunctional primary amine and/or a tetrafunctional primary amine and optionally with a difunctional primary amine. The branched polymeric biguanide compounds have 2-dimensional conformation that provides better coverage over the surfaces of microorganisms and enhances efficacy as biocides as compared to most commercially available linear (one-dimensional) polymeric biguanide compounds. The bulkier 2-dimensional conformation of this invention limits the uptake, accumulation and release of these branched polymers to and from contact lenses. Therefore, these branched biguanide polymers can reduce the cytotoxicity, enhance compatibility and suitable for ophthalmic use. The highly branched polymers can be prepared with minimum or no difunctional primary amines. The lightly branched polymers can be prepared with of a minimum ratio of trifunctional plus multifunctional primary amines to difunctional primary amines.

Branched polymeric biguanide compounds and their uses

Biocidal branched quaternary ammonium polymers are made by condensing a difunctional halide with a trifunctional tertiary amine and optionally with a difunctional amine. The branched quaternary ammonium polymers have 2-dimensional conformation that provides better coverage over the surfaces of microorganisms and enhances efficacy as biocides as compared to most commercially available linear (one-dimensional) quaternary ammonium polymers. The bulkier 2-dimensional conformation of this invention limits the uptake, accumulation and release of these branched polymers to and from contact lenses. Therefore, these branched quaternary ammonium polymers can reduce the cytotoxicity, enhance compatibility and suitable for ophthalmic use. The highly branched polymers can be prepared with minimum or no difunctional tertiary amines. The lightly branched polymers can be prepared with of a minimum ratio of trifunctional tertiary amines/difunctional tertiary amines.

Branched polymeric quaternary ammonium compounds and their uses

New polymeric quaternary ammonium compounds with vicinal hydroxyl groups are disclosed. These compounds are useful as disinfectants in contact lens care compositions and/or as preservatives in ophthalmic compositions. Compositions containing these compounds are also disclosed. These compositions are especially useful for disinfecting/cleaning contact lenses.

Polymeric quaternary ammonium compounds with vicinal hydroxy groups

The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.

Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions

Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions

Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.

(Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure

Novel dioxinoindazole compounds and dioxoloindazole compounds are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions of one or more of the compounds of the present invention.

Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Compounds with 5HTreceptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.

[object Object]

Substituted pyranoindoles useful for lowering and controlling IOP and glaucoma are disclosed.

Pyranoindoles for treating glaucoma

An improved fish finding device and method for detecting and distinguishing marine life from a sonar reflected marker that generates artificial echoes comprises steps of 1. transmitting of sonar waves 2. receiving of sonar echoes 3. distinguishing the sonar echoes reflected from a sonar reflected marker from the marine life by the difference of frequency, intensity, waveform and duration of the echoes and converting echoes into signal using a microprocessor and 4. displaying the echoes signal of the sonar reflected marker as an icon different from that of the marine life. The relative distance of the sonar reflected marker and the marine life could also be calculated by a microprocessor. A fish nearby alarm sounds when fish swims within a preset value of distance. The improved fish finding device and the fish finding method guide the user to adjust accurately the bait next to fish. The improved fish finding device also alarms the user that fish is nearby the bait when a sonar reflected maker is used and placed next to the bait.

Fish finding device and method for detecting and distinguishing marine life from a sonar reflected marker

A sounding device for showing its location on a sonar fish detector including a sonar wave receiving unit () to detect the sonar signal, a sonar wave producing unit () to simulate the reflection of the sonar wave from the fish, a control unit () to regulate the function of the wave receiving and producing units through on-off switches () and (), and a power supply () to provide the electricity for the sounding device. The control unit may also receive command remotely from a sonar fish detector or a remote controller to turn on/off the sounding device as well as to perform other functions.

Sounding device for showing its location on a fish detector

Pyranoindazoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.

Growing community of inventors

Fort Worth, TX, United States of America

Hwang-Hsing Chen